Rodos BioTarget

About:

Rodos BioTarget (RBT) is a biopharmaceutical company developing a targeted drug delivery platform, TargoSphere®.

Website: http://www.biotargeting.eu

Top Investors: Aescuvest, HTGF | High-Tech Gruenderfonds, Enjoyventure Management, ERP Startfonds, Business Angels Agentur Ruhr

Description:

Rodos BioTarget (RBT) is a biopharmaceutical company developing a targeted drug delivery platform. RBT’s patented TargoSphere® technology enables carrying a broad range of active agents selectively into the center of the immune response - i.e., directly into antigen-presenting cells. RBT currently applies its TargoSphere® technology successfully in various models of infectious diseases caused by viruses like HCV/ Hepatitis C and HIV/ AIDS and by bacteria like in Tuberculosis, Legionellosis, and MRSA. Yet, any disorder that goes along with either overshooting or insufficient immunity caused by antigen-presenting cells - like chronic inflammations, cancers, allergies, and autoimmune diseases - may be addressed by RBT’s TargoSphere® technology.